<DOC>
	<DOCNO>NCT00920595</DOCNO>
	<brief_summary>An open-label study evaluate safety , pharmacokinetics , pharmacodynamics CEP-9722 single-agent therapy combination therapy temozolomide patient advance solid tumor .</brief_summary>
	<brief_title>Study CEP-9722 Single-Agent Therapy Combination Therapy With Temozolomide Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>The patient histologically cytologically confirm malignant advance solid tumor consider unresponsive poorly responsive accept treatment modality . The patient adequate hematologic assessment adequate renal hepatic function specify study protocol . The patient measurable nonmeasurable disease document appropriate method evaluation accord disease characteristic . The patient chemotherapy least 3 week resolution prior sequelae . If patient prior curative radiation prior treatment nitrosoureas , minimum 4 week 6 week , respectively , must elapse treatment CEP9722 . The patient immunotherapy , include monoclonal antibody therapy , least 4 week hormonotherapy least 1 week , exception patient prostate cancer , may continue hormonal therapy . The patient European Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . The patient life expectancy 12 week . Agreement woman childbearing potential ( surgically sterile 2 year postmenopausal ) use medically accept method contraception continue use method duration study 90 day participation study . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . Agreement men surgically sterile capable produce offspring practice abstinence use barrier method birth control , continue use method duration study 6 month participation study . The patient primary brain tumor whose disease require systematic premedication anticonvulsive agent . The patient baseline cardiac abnormality outside specify study parameter . The patient clinically symptomatic recurrent/progressive brain metastasis within 4 week ( stable sequela acceptable ) . The patient previous hypersensitivity reaction 1 component CEP9722 , temozolomide , dacarbazine . The patient pregnant breastfeed woman . ( Any woman become pregnant study withdrawn study . ) The patient participate another interventional clinical study time enrollment , participate another interventional clinical study within 4 week prior enrollment , patient previously already enrol study . The patient active gastroduodenal ulcer , uncontrolled high blood pressure , uncontrolled diabetes mellitus , uncontrolled angina pectoris ; recent myocardial infarction ; cerebrovascular event within 6 month prior study entry ; preexist coagulopathy . The patient concomitant uncontrolled infection severe systemic disease . The patient know nephropathy hepatopathy . The patient receive concurrent treatment antineoplastic agent temozolomide . The patient previous treatment another PARP inhibitor . The patient unable swallow capsule . The patient take medication contraindicate specify study protocol . The patient serious uncontrolled nonmalignant medical disorder psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer</keyword>
</DOC>